



US 20020025524A1

(19) **United States**

(12) **Patent Application Publication**

Cook et al.

(10) **Pub. No.: US 2002/0025524 A1**

(43) **Pub. Date: Feb. 28, 2002**

(54) **ASPERGILLUS N-MYRISTOYL
TRANSFERASE GENES AND
POLYPEPTIDES AND USES THEREOF**

(75) Inventors: **W. James Cook**, Natick, MA (US);
Christine E. Bulawa, Arlington, MA
(US)

Correspondence Address:
J. PETER FASSE
Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804 (US)

(73) Assignee: **Millennium Pharmaceuticals, Inc., a
Delaware corporation**

(21) Appl. No.: **09/858,075**
(22) Filed: **May 15, 2001**

Related U.S. Application Data

(62) Division of application No. 09/163,444, filed on Sep.
30, 1998, now Pat. No. 6,251,596.

Publication Classification

(51) **Int. Cl.⁷** **C12Q 1/68**; C07H 21/02;
C07H 21/04; C12P 19/34;
C12N 1/12; C12N 1/20; C12N 15/00;
C12N 15/09; C12N 15/63;
C12N 15/70; C12N 15/74
(52) **U.S. Cl.** **435/6**; 435/91.2; 435/320.1;
435/252.1; 536/23.1

(57) **ABSTRACT**

Disclosed is an *Aspergillus fumigatus* N-myristoyltrans-
ferase gene and its use in identifying antifungal agents, for
example.

Aspergillus fumigatus NMT

1	ATGGCGAGTCGCTATTGGAAAAACAACCCCGCTCTCAGGAACGAGACGGCCGCGCATGGACAAGACAAAGCGGAGGCAATGGCGAAATGAACATTG	100
	M A E S L L E N N P A L R N E T A G M D K D K A A E A M R K M N I A	
101	CCGAATTGCTGACAGGCTTGTCAGTTTCCGGGAAGAACCAAGGATATGGCTTCGTACAAGTTTGGCAAACGCAGCCTGTGCCCCGATTTCGATGAGAC	200
	E L L T G L S V S G K N Q K D M A S Y K F W Q T Q P V P R F D E T	
201	GAGTACCGATACTGGGGGCCCTATCAAGATCATTGATCCTGAAAAGGTCTCAAAGGAACCGGATCGCTGCTTGAAGGATTTGAATGGGCGACACTCGAC	300
	S T D T G G P I K I I D P E K V S K E P D A L L E G F E W A T L D	
301	CTGACAAACGAGACTGAGCTGCAGGAGCTGTGGGATTTGTTGACGTATCACTACGTAGAGGACGACAATGCCATGTTCCGGTTTCAGATATTCGACGTCGT	400
	L T N E T E L Q E L W D L L T Y H Y V E D D N A M F R F R Y S Q S F	
401	TCCTACACTGGGCTTTATGTCGCCTGGCTGGAAAAAGGAATGGCATGTCCGCGCTACGAAAGTCGGCGAAACTGGTAGCGTCCATTTCGGGTGT	500
	L H W A L M S P G W K K E W H V G V R A T K S R K L V A S I C G V	
501	CCCGACAGAGATCAATGTGGGCAATCAAAGCTCAAGGTCGTCGAGATCAATTTCCCTCTGCATCCACAAGAGCTCCGCTCGAAGCGCTTGACCCCGATT	600
	P T E I N V R N Q K L K V V E I N F L C I H K K L R S K R L T P V	
601	CTCATCAAAGAAATCACCCTGCTTGTACCTCAATGGCATCTACCAAGCCATCTACACTGCGGGTGTGTGCTCCCACTCCTGTGAGCTCATGCCGCT	700
	L I K E I T R R C Y L N G I Y Q A I Y T A G V V L P T P V S S C R Y	

FIG. 1A

701	ACTACCAACCGTCCTTTGGACTGGTTGAAGCTTTACGAGTCGGCTTCTCGCCTCTCCCTGCCGATCCACCAAGCGCGCCAGATCACCAGAATCACCT Y H R P L D W L K L Y E V G F S P L P A G S T K A R Q I T K N H L	800
801	GCCCAGTACTACCTCTACCCCGGTCTTCGCCCCCATGGAGCCCAAGACATTGACACAGTGCATGATCTTTTGACGCGATACTTGTGCGGTTGCGTTG P S T T S T P G L R P M E P K D I D T V H D L L Q R Y L S R F A L	900
901	AACCAGGCCTTTACGGGAGAGGAAGTGGACCATTTGGCTCGTGCAACAGCCGGAGACGGTGAAGAGCAGGTCTGTGGCATACGTGGTAGAGACCCCTG N Q A F T R E E V D H W L V H K P E T V K E Q V V W A Y V V E D P E	1000
1001	AAACGGACAAGATCACCGACTTCTTTTCCTTCTACAACTCGAATCCACCGTCATTGAGATCCCAAGCATGACAATGTGCGTCTGCTTACCTGTACTA T H K I T D F F S F Y N L E S T V I Q N P K H D N V R A A Y L Y Y	1100
1101	CTATGCAACCGAAACAGCTTACCAATAACATGAAGGCTCTCAAGAGCGTCTGCTGATGCTGATGAATGACGCTCTGATCCTGGCTAAGAAGGCGCAC Y A T E T A F T N N M K A L K E R L L M L M N D A L I L A K K A H	1200
1201	TTTGATGTGTTCAACGCACCTTACGCTTCACGATAACCCCTCTGTTCCCTCGAACAACTCAAATTTGGAGCTGGCGATGGCAGCTTCACTTCTACCTCTACA F D V F N A L T L H D N P L F L E Q L K F G A G D G Q L H F Y L Y N	1300
1301	ACTATCGCACCGCCCTGTTCTCTGGAGGAGTTAACGAGAAGAACCTGCCGATGAGAAAAGAAATGGAGCGTTGGCATCGTTATGCTGTAA Y R T A P V P G G V N E K N L P D E K R M G G V G I V M L *	1392

(SEQ ID NO:1)

(SEQ ID NO:2)

FIG. 1B

nm1 (Aspergillus fumigatus)

1	TCCGAC	TCTAAG	GATCGCA	AGGCAAG	CCCCCGAG	GCAGTC	TTCCGAAA	AGAAAGAT	TGGCGCGG	TGAACAT	AACCCCT	CAGATG	CGCGAG	TCGCTAT	AGGTGAG	ATTCTAG	CGTTCCCG	GTCCCGGT	CAGAAAG	CGTTTCT	TCTACCG	CGCCACT	TGTAT	TGGGAG	TCTAC	CGCCT	CAGCGATA	100													
1	M A E S L L 6																																								
101	TGGAAA	CAACACC	CCGCTCT	CAGGAAC	GAGACG	CGCCGCGCAT	GGACAA	AGACAAG	CGCGGAGG	CAATCG	CAAAAT	GAACAT	TGCGGAA	TTGCTG	ACAGG	ACCTTT	TGTGGG	CGGAGATC	TGCTGT	TCTGT	CCGCGCT	CCGTTAC	GGCTTT	TACTT	GTAAAC	GGCTTA	AACGACT	GTCC	200												
7	E N N	P A L	R N E	T A G	M D K	D K A	E A E	A M R	K M N	I A E	L L T	G	39																												
201	CTTGT	CAGTTT	CCGGAAG	AACCA	GAGGAT	ATGGCTT	CGTACA	AGTTT	TGGCAA	ACGAGC	CTGTG	CCCCGAT	TGATG	AGACG	AGTAC	CGATAC	TGGG	GAACAG	TCAAGG	CCCTTCT	TATAC	CGAAGCAT	GTTC	AAAAAC	CGTTT	GGTTC	GGACAC	CGGCGCT	TAAGCT	ACTCT	GCTCAT	CGCTAT	GACCC	300							
40	L S V	S G K	N Q K	D M A	S Y K	F W Q	T Q P	V P R	F D E	T S T	D T G	72																													
301	GGCCCT	ATCAAG	ATCAT	TGATC	CTGAA	AGGTCT	CAAGGA	ACCGAT	CGCTG	CTTGA	AGGATTT	GAA	TGGCG	CACACT	CGACCT	TGACAA	ACGAGACT	CGGGAT	AGTTCT	AGTAAC	TAGGACT	TTTCC	CAGAGTT	TCCCT	TGGCT	TACGG	CAGCACT	TCC	TAACT	TACCCG	CTGTG	AGCTGG	ACTGTT	TGCTCT	GAC	400					
73	G P I	K I I	D P E	K V S	K E P	D A L	E G F	E W A	T L D	L T N	E T E	106																													
401	AGCTG	CAGGAC	TGTGGG	ATTGTT	GACGTA	TCACTAC	GTAAG	AGACG	ACAAT	TGCCAT	GTTC	CGGTT	CAGATAT	TGCGAG	TCTG	TTCC	TACACT	TGTTGG	TGAC	AGTCT	TAACAA	CTGCAT	CTCCT	GCTGT	TACG	TACA	AGGCCA	AGTCT	ATA	AGCGT	CAGCA	AGGAT	GTGAC	CAACCCA	500						
107	L Q E	L W D	L L T	Y H Y	V E D	D N A	M F R	F R Y	S Q S	F L H	W	137																													
501	GCACA	ACGGCC	GAGGGA	TCTGTTT	CTCAC	CGGCTT	GGAGG	TGTGGATT	ATTT	GAGCG	CTGACA	ATTTT	GACCG	CTGACA	ATTTT	GACCG	TAGGG	CTCTT	ATGTC	GCCTGG	CTCGT	TTGCG	CGGCT	CCCT	TAGACA	AAGAGT	GGCGGA	ACCT	TCC	CACAC	CTAATA	AACTCG	CGACT	GTTTAA	AACTGG	CAATCC	CGAGATA	TACAG	CGGAC	CGGA	600
138	A L M S P G W 144																																								

601	GGAAAAGGAATGGCATGTCGGTGTCCGGCTACGAAGTCGCGCAAACTGGTAGCGTCCCAATTTGCGGTGTCCGGACAGATCAATGTGCGCAATCAAAA CCTTTTTCCTTACCGTACAGCCACAGCGCGATGCTTCAGCGCGTTTGACCATCGCAGGTAAACGCCACAGGCTGTCTCTAGTTACACCGGTTAGTTT	700
145	KK E W H V G V R A T K S R K L V A S I C G V P T E I N V R N Q K	177
701	GCTCAAGGTGTCGAGATCAATTTCTCTGCATCCACAAGAAGTCGCGTCCGAAGCGCTTGACCCAGTTCTCATCAAGAAGAAATCACCCGTCGTTGCTAC CGAGTCCAGCAGCTCTAGTTAAAGGAGACGTAGGTGTTCTTCGAGGCGAGCTTCGCGAACTGGGTCAAGAGTAGTTTCTTAGTGGGAGCAACGATG	800
178	L K V V E I N F L C I H K K L R S K R L T P V L I K E I T R R C Y	210
801	CTCAATGGCATCTACCAAGCCATCTACACTGCGGGTGTGGTCTCCCACTCTCTGTCTCAGCTCATGCCGCTACTACCAACCGTCTCTTTGGACTGGTTGAAGC GAGTTACCGTAGATGGTTTCGGTAGATGTGACGCCACACACGAGGGGTGAGGACAGTCGAGTACGGCGATGATGGTGGCAGGAAACCTGACCAACTTCG	900
211	L N G I Y Q A I Y T A G V V L P T P V S S C R Y Y H R P L D W L K L	244
901	TTTACGAGGTGCGCTTCTCGCTCTCCCTGCGGATCCACCAAGCGCGCCAGATACCAAGAATCACCTGCCCACTACTACTCTACCCCGGCTCTCG AAATGCTCCAGCCGAGAGCGGAGGAGCGCTAGGTGGTTCCCGCGGCTCTAGTGGTCTTAGTGACGGGTCTATGATGAGATGGGGGCCAGAAGC	1000
245	Y E V G F S P L P A G S T K A R Q I T K N H L P S T T S T P G L R	277
1001	CCCATGGAGCCCAAGACATTCACACAGTCATGATCTTTTCAGCGATACTTTCGCGGTTTTCGTTGAACCAAGCCCTTTACCGCAGAGGAGTGGAC GGGTACCTCGGTTTCTGTAAGTGTCTCAGGTACTAGAAAGGTGCGTATGAACAGCGCCAAACGCAACTTGGTCCGGAATGCGCTCTCCTTCACCTG	1100
278	P M E P K D I D T V H D L L Q R Y L S R F A L N Q A F T R E E V D	310
1101	CATTGGCTCTGCACAAGCCGGAGACGGTGAAGAGCAGGTCTGCTGGGCATACGTGGTAGAGGACCTTGAAACGCACAAAGATCACCGACTTCTTTTCCT GTAAACGAGCAGCTGTTCGGCTCTGCCACTTCTCGTCCAGCAGACCGGTATGCACCACTCTCTGGACTTTGCGTGTCTAGTGTGCTGAAGAAAGGA	1200
311	H W L V H K P E T V K E Q V V W A Y V V E D P E T H K I T D F F S F	344
1201	TCTACAACTCGAATCCACCGTCAATTCAGAAATCCCAAGCATGACAAATGTGCGTGTCTGTACCTGTACTACTATGCAACGAAACAGCTTTCACCAATAA AGATGTTGGAGCTTAGGTGGCAGTAAGTCTTAGGTTTCGTACTGTTACAGCGACGACGATGGACATGATGATACGTTGGCTTTGCGAAAGTGGTTATT	1300
345	Y N L E S T V I Q N P K H D N V R A A Y L Y Y A T E T A F T N N	377

FIG. 2B

1301	CATGAAGGCTCTCAAAGAGCGTCTGCTGATGCTGATGAATGACGCTTGATCCCTGGCTAAGAAGGTAACCTACAGGGATCCACTGCCATTTCCCTGGAGTT	1400
	GTACTTCCGAGAGTTCTCGCAGACGACTACGACTACTTACTGCGAGACTAGGACCGATCTCTTCCAATTGATGTCCTAGGTGACGGTAAAGGACCTCAA	
378	M K A L K E R L L M L M N D A L I L A K K A	399
1401	GACTTACGAAGCTGACATTGTGTTGATAGGCGCACTTTGATGTGTTCAACGCCACTTACGCTTCACGATAACCCCTCTGTTCTCGAACAACTCAAATTTGG	1500
	CTGAATGCTTCGACTGTAAACACACAACTATCCGCGTGAACTACACAAGTTGCGTGAATGCGAAGTGCTATTGGGAGACAAAGGAGCTGTGTAGTTTAAACC	
400	H F D V F N A L T L H D N P L F L E Q L K F G	422
1501	AGCTGGCGATGGGAGCTTCACTTCTACCTCTACAACCTATCGACCCCTGTTCTGGAGGAGTTAACGAGAAGAACCCTGCCGGATGAGAAAAGAATG	1600
	TCGACCGCTACCCGTCGAAGTGAAGATGGAGATGTTGATAGCGTGGGGGACAAAGGACCTCCTCAATTGCTCTTCTTGGACGGCCTACTCTTTTCTTAC	
423	A G D G Q L H F Y L Y N Y R T A P V P G G V N E K N L P D E K R M	455
1601	GGAGGCGTTGGCATCGTTATGCTGTAAACATTTCTACCGCATGGACCATGCCCTCGCCTCGTTTGATGATCGCATCTTTATACCTATTTCTCGCTGTGAC	1700
	CCTCCGCAACCGTAGCAATACGACATTTTGTAAGAGTGGCGTACCTGGTACGGAGAGCGGAGCAACTACTAGCGTAGAATATGGATAAAGAGCGACACTG	
456	G G V G I V M L *	463

1701	ATGAATTTGGGTATCGGAAATACCATGAAAATTTG	1735	(SEQ ID NO:3)
	TACTTAAACCATAGGCTTTATGGTACTTTTAAAC		(SEQ ID NO:2)

FIG. 2C

ASPERGILLUS N-MYRISTOYL TRANSFERASE GENES AND POLYPEPTIDES AND USES THEREOF

FIELD OF THE INVENTION

[0001] The invention relates to N-myristoyl transferase of the fungus *Aspergillus fumigatus* and its use in identifying antifungal agents.

BACKGROUND OF THE INVENTION

[0002] The enzyme N-myristoyl transferase (NMT) is responsible for cotranslational modification of a variety of fungal proteins. NMT catalyzes the attachment of a 14-carbon saturated fatty acid to the N-terminal glycine residue of cellular proteins. This modification is thought to be irreversible and essential for the full biological activity of myristoylated proteins.

SUMMARY OF THE INVENTION

[0003] The invention is based on the discovery of an NMT gene in the fungus *Aspergillus fumigatus*. The *Aspergillus* NMT coding sequence is depicted in **FIG. 1** as SEQ ID NO:1, with the amino acid sequence represented by SEQ ID NO:2. The NMT genomic sequence is depicted in **FIG. 2** as SEQ ID NO:3.

[0004] The NMT gene of the invention is essential for survival of *Aspergillus*. Accordingly, the NMT nucleic acid sequence of the invention, and the NMT polypeptide of the invention, are useful targets for identifying compounds that are inhibitors of *Aspergillus*. Such inhibitors attenuate fungal growth by inhibiting the activity of the essential NMT polypeptide, or by inhibiting transcription or translation. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding *Aspergillus* NMT polypeptides or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of NMT-encoding nucleic acids (e.g., fragments of at least 15 nucleotides (e.g., at least 18, 20, or 25 nucleotides)).

[0005] The invention features a nucleic acid molecule which is at least 65% (or 75%, 85%, 95%, or 98%) identical to the nucleotide sequence shown in SEQ ID NO:1, or SEQ ID NO:3, or the nucleotide sequence of the cDNA insert of the plasmid deposited with ATCC as Accession Number (the "cDNA of ATCC _____"), or a complement thereof.

[0006] The invention features a nucleic acid molecule which includes a fragment of at least 300 (e.g., 325, 350, 375, 400, 425, 450, 500, 550, 600, 650, 700, 800, 900, 1000, 1200, 1400, 1600, or 1770) nucleotides of the nucleotide sequence shown in SEQ ID NO:1, or SEQ ID NO:3, or the nucleotide sequence of the cDNA ATCC _____, or a complement thereof.

[0007] The invention also features a nucleic acid molecule which includes a nucleotide sequence encoding a protein having an amino acid sequence that is at least 65% (or 75%, 85%, 95%, or 98%) identical to the amino acid sequence of SEQ ID NO:2 or the amino acid sequence encoded by the cDNA of ATCC _____.

[0008] Also within the invention is a nucleic acid molecule that encodes a fragment of a polypeptide having the

amino acid sequence of SEQ ID NO:2, the fragment including at least 15 (25, 30, 50, 100, 150, 300, 400, or 450) contiguous amino acids of SEQ ID NO:2 or the polypeptide encoded by the cDNA of ATCC Accession Number _____.

[0009] In other embodiments, the invention features an isolated NMT protein having an amino acid sequence that is at least about 65% (e.g., 75%, 85%, 95%, or 98%) identical to the amino acid sequence of SEQ ID NO:2; and an isolated NMT protein which is encoded by a nucleic acid molecule having a nucleotide sequence that is at least about 65% (e.g., 75%, 85%, or 95%) identical to SEQ ID NO:1 or the cDNA of ATCC _____; and an isolated NMT protein which is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 or the non-coding strand of the cDNA of ATCC _____.

[0010] Another embodiment of the invention features NMT nucleic acid molecules which specifically detect *Aspergillus* NMT nucleic acid molecules relative to nucleic acid molecules encoding other N-myristoyltransferases. For example, in one embodiment, an *Aspergillus* NMT nucleic acid molecule hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, or the cDNA of ATCC _____, or a complement thereof. In another embodiment, the *Aspergillus* NMT nucleic acid molecule is at least 300 (e.g., 400, 500, 700, 900, 1100, or 1300) nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, the cDNA of ATCC _____, or a complement thereof. In another embodiment, the invention provides an isolated nucleic acid molecule which is antisense to the coding strand of an *Aspergillus* NMT nucleic acid.

[0011] Another aspect of the invention provides a vector, e.g., a recombinant expression vector, comprising an NMT nucleic acid molecule of the invention. In another embodiment the invention provides a host cell containing such a vector. The invention also provides a method for producing NMT protein by culturing, in a suitable medium, a host cell of the invention containing a recombinant expression vector such that a NMT protein is produced.

[0012] Another aspect of this invention features isolated or recombinant NMT proteins and polypeptides. Preferred NMT proteins and polypeptides possess at least one biological activity possessed by naturally occurring *Aspergillus* NMT, e.g., an ability to catalyze transfer of myristate from myristoyl-CoA to the N-terminal glycine residue of a polypeptide. It is not necessary that the NMT polypeptide have an N-myristoyltransferase activity that is equivalent to that of the wild-type *Aspergillus* NMT. For example, the NMT polypeptide can have 20, 50, 75, 90, 100, or an even higher percent of the wild-type activity.

[0013] Now that the *Aspergillus* NMT gene, which is essential for survival, has been identified, nucleic acids encoding *Aspergillus* NMT and *Aspergillus* NMT proteins can be used to identify antifungal agents. Such antifungal agents can readily be identified with high throughput assays to detect inhibition of NMT activity. This inhibition can be caused by small molecules binding directly to the NMT polypeptide or by binding of small molecules to other essential polypeptides in that pathway.

[0014] In an exemplary, but not the only assay, a compound is tested for its ability to inhibit *Aspergillus* NMT in an assay of NMT activity. NMT activity can be assayed by measuring incorporation of labeled myristate (e.g., [^3H]myristate) in culture. The effect of a test compound can be determined by adding the test compound to the culture containing the labeled myristate, then comparing the level of labeled myristate in the culture with the level obtained in control cultures. Now that the *Aspergillus fumigatus* NMT gene has been identified, it can readily be cloned into various host cells (e.g., fungi, *E. coli* or yeast) for carrying out such assays in whole cells. Similarly, conventional in vitro assays of NMT activity can be used with the NMT of the invention.

[0015] A suitable NMT activity assay has been described by Stone et al., *Genes and Dev.* 5:1969-1981 (1991), which is incorporated herein by reference. Briefly, [^3H]myristate is added to cell cultures to specifically label myristoylated proteins, which can be separated by SDS-PAGE and visualized by autoradiography. The level of myristoylation can subsequently be quantitated by using conventional methods to measure incorporation of [^3H]myristate.

[0016] In an alternative assay, a promoter that responds to depletion of the NMT polypeptide by upregulation or downregulation is linked to a reporter gene. To identify a promoter that is up- or down-regulated by the depletion of the NMT polypeptide, the gene encoding *Aspergillus* NMT is deleted from the genome and replaced with a version of the gene in which the sequence encoding the NMT protein is operably linked to a regulatable promoter. The cells containing this regulatable genetic construct are kept alive by the NMT produced from the genetic construct containing the regulatable promoter. However, the regulatable promoter allows the expression of NMT to be reduced to a level that causes growth inhibition. Total RNA prepared from *Aspergillus* under such growth-limiting conditions is compared with RNA from wild-type cells. Standard methods of transcriptional profiling can be used to identify mRNA species that are either more or less abundant (i.e., up- or down-regulated) when expressed under the limiting conditions. Genomic sequence information, e.g., from GenBank, can be used to identify the promoter that drives expression of the identified RNA species. Such promoters are up- or down-regulated by depletion of the NMT polypeptide.

[0017] Having identified a promoter(s) that is up- or down-regulated by depletion of the NMT polypeptide, the promoter(s) is operably linked to a reporter gene (e.g., β -galactosidase, *gus*, or GFP). A fungal strain containing this reporter gene construct is then exposed to test compounds. Compounds that inhibit the essential polypeptide (or other polypeptides in the essential pathway in which the NMT polypeptide participates) will cause a functional depletion of the NMT polypeptide and therefore lead to an upregulation or downregulation of expression the reporter gene. Because NMT is essential for the survival of *Aspergillus*, compounds that inhibit NMT in such an assay are expected to have antifungal activity and can be further tested, if desired, in standard susceptibility assays.

[0018] Another suitable method for identifying antifungal compounds involves screening for small molecules that specifically bind to an NMT polypeptide. A variety of suitable binding assays are known in the art as described, for

example, in U.S. Pat. Nos. 5,585,277 and 5,679,582, hereby incorporated herein by reference. For example, in various conventional assays, test compounds can be assayed for their ability to bind an NMT polypeptide by measuring the ability of the small molecule to stabilize the NMT polypeptide in its folded, rather than unfolded, state. More specifically, one can measure the degree of protection against unfolding that is afforded by the test compound. Test compounds that bind the NMT polypeptide with high affinity cause, for example, a large shift in the temperature at which the polypeptide is denatured. Test compounds that stabilize the polypeptide in a folded state can be further tested for antifungal activity in a standard susceptibility assay.

[0019] In a related method for identifying antifungal compounds, an NMT polypeptide is used to isolate peptide or nucleic acid ligands that specifically bind the NMT polypeptides. These peptide or nucleic acid ligands are then used in a displacement screen to identify small molecules that bind to the NMT polypeptide. Such binding assays can be carried out essentially as described above.

[0020] The *Aspergillus* NMT polypeptides also can be used, in assays to identify test compounds that bind to the polypeptides. Test compounds that bind the NMT polypeptides then can readily be tested, in conventional assays, for their ability to inhibit fungal growth. Test compounds that bind the essential polypeptides are candidate antifungal agents, in contrast to compounds that do not bind the essential polypeptides. As described herein, any of a variety of art-known methods can be used to assay for binding of test compounds to the essential polypeptides.

[0021] The invention includes, for example, a method for identifying an antifungal agent where the method entails: (a) contacting an NMT polypeptide with a test compound; (b) detecting binding of the test compound to the polypeptide; and (c) determining whether a test compound that binds to the polypeptide inhibits growth of *Aspergillus*, relative to growth of fungi cultured in the absence of the test compound that binds to the NMT polypeptide, as an indication that the test compound is an antifungal agent.

[0022] In still another method, binding of a test compound to an NMT polypeptide can be detected in a conventional two-hybrid system for detecting protein/protein interactions (e.g., in yeast or mammalian cells). A test compound found to bind the essential polypeptide can be further tested for antifungal activity in a conventional susceptibility assay. Generally, in such two-hybrid methods, (a) the essential polypeptide is provided as a fusion protein that includes the polypeptide fused to (i) a transcription activation domain of a transcription factor or (ii) a DNA-binding domain of a transcription factor; (b) the test polypeptide is provided as a fusion protein that includes the test polypeptide fused to (i) a transcription activation domain of a transcription factor or (ii) a DNA-binding domain of a transcription factor; and (c) binding of the test polypeptide to the polypeptide is detected as a reconstitution of a transcription factor. Reconstitution of the transcription factor can be detected, for example, by detecting transcription of a gene that is operably linked to a DNA sequence bound by the DNA-binding domain of the reconstituted transcription factor (See, for example, White, 1996, *Proc. Natl. Acad. Sci.* 93:10001-10003 and references cited therein and Vidal et al., 1996, *Proc. Natl. Acad. Sci.* 93:10315-10320).

[0023] In an alternative method, an isolated nucleic acid molecule encoding an NMT is used to identify a compound that decreases the expression of NMT in vivo (i.e. in an *Aspergillus* cell). Such compounds can be used as antifungal agents. To discover such compounds, cells that express an NMT are cultured, exposed to a test compound (or a mixture of test compounds), and the level of NMT expression or activity is compared with the level of NMT expression or activity in cells that are otherwise identical but that have not been exposed to the test compound(s). Standard quantitative assays of gene expression and NMT activity can be utilized in this aspect of the invention.

[0024] To identify compounds that modulate expression of NMT the test compound(s) can be added at varying concentrations to the culture medium of *Aspergillus*. Such test compounds can include small molecules (typically, non-protein, non-polysaccharide chemical entities), polypeptides, and nucleic acids. The expression of NMT is then measured, for example, by Northern blot PCR analysis or RNase protection analyses using a nucleic acid molecule of the invention as a probe. The level of expression in the presence of the test molecule, compared with the level of expression in its absence, will indicate whether or not the test molecule alters the expression of the essential polypeptide. Because NMT is essential for survival, test compounds that inhibit the expression and/or function of NMT will inhibit growth of, or kill, the cells that express NMT.

[0025] Typically, the test compound will be a small organic molecule. Alternatively, the test compound can be a test polypeptide (e.g., a polypeptide having a random or predetermined amino acid sequence; or a naturally-occurring or synthetic polypeptide) or a nucleic acid, such as a DNA or RNA molecule. The test compound can be a naturally-occurring compound or it can be synthetically produced, if desired. Synthetic libraries, chemical libraries, and the like can be screened to identify compounds that bind NMT. More generally, binding of a test compound to an NMT polypeptide can be detected either in vitro or in vivo. If desired, the above-described methods for identifying compounds that modulate the expression of the NMT polypeptides of the invention can be combined with measuring the levels of NMT expressed in cells, e.g., by carrying out an assay of NMT activity, as described above or, for example, performing a Western blot analysis using antibodies that bind NMT. The antifungal agents identified in the methods of the invention can be used to inhibit a wide spectrum of pathogenic or non-pathogenic fungal strains.

[0026] The invention includes pharmaceutical formulations that include a pharmaceutically acceptable excipient and an antifungal agent identified using the methods described herein. In particular, the invention includes pharmaceutical formulations that contain antifungal agents that inhibit the growth of, or kill, pathogenic fungal strains (e.g., pathogenic *Aspergillus fumigatus* strains). Such pharmaceutical formulations can be used in a method of treating a fungal infection in an organism. Such a method entails administering to the organism a therapeutically effective amount of the pharmaceutical formulation, i.e., an amount sufficient to ameliorate signs and/or symptoms of the fungal infection. In particular, such pharmaceutical formulations can be used to treat fungal infections in mammals such as humans and domesticated mammals (e.g., cows, pigs, dogs, and cats), and in plants. The efficacy of such antifungal

agents in humans can be estimated in an animal model system well known to those of skill in the art (e.g., mouse systems of fungal infections).

[0027] Various affinity reagents that are permeable to the microbial membrane (i.e., antibodies and antibody fragments) are useful in practicing the methods of the invention. For example polyclonal and monoclonal antibodies that specifically bind to the *Aspergillus* NMT polypeptide can facilitate detection of *Aspergillus* NMT in various fungal strains (or extracts thereof). These antibodies also are useful for detecting binding of a test compound to NMT (e.g., using the assays described herein). In addition, monoclonal antibodies that specifically bind *Aspergillus* NMT can themselves be used as antifungal agents.

[0028] In another aspect, the invention features a method for detecting an *Aspergillus* NMT polypeptide in a sample. This method includes: obtaining a sample suspected of containing an *Aspergillus* NMT polypeptide; contacting the sample with an antibody that specifically binds to an *Aspergillus* NMT polypeptide under conditions that allow the formation of complexes of an antibody and the NMT polypeptide; and detecting the complexes, if any, as an indication of the presence of an *Aspergillus* NMT polypeptide in the sample.

[0029] The invention offers several advantages. For example, the methods for identifying antifungal agents can be configured for high throughput screening of numerous candidate antifungal agents. Because the NMT gene disclosed herein is thought to be highly conserved, antifungal drugs targeted to this gene or its gene products are expected to have a broad spectrum of antifungal activity.

[0030] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described herein. All publications, patent applications, patents, and other references mentioned herein are incorporated herein by reference in their entirety. In the case of a conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative and are not intended to limit the scope of the invention, which is defined by the claims.

[0031] Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0032] FIG. 1 is a listing of the nucleotide sequence (SEQ ID NO:1) and predicted amino acid sequence (SEQ ID NO:2) of *Aspergillus fumigatus* N-myristoyl transferase (NMT).

[0033] FIG. 2 is a listing of the genomic (SEQ ID NO:3) and predicted amino acid sequences (SEQ ID NO:2) of *Aspergillus fumigatus* NMT.

DETAILED DESCRIPTION OF THE INVENTION

[0034] A gene encoding N-myristoyltransferase of *Aspergillus fumigatus* has been identified and is essential for

the survival of *Aspergillus*. The NMT gene and polypeptide are useful targets for identifying compounds that are inhibitors of the fungi in which NMT polypeptides are expressed.

[0035] Nucleic acids include both RNA and DNA, including genomic DNA and synthetic (e.g., chemically synthesized) DNA. Nucleic acids can be double-stranded or single-stranded. Where single-stranded, the nucleic acid may be a sense strand or an antisense strand. Nucleic acids can be synthesized using oligonucleotide analogs or derivatives (e.g., inosine or phosphorothioate nucleotides). Such oligonucleotides can be used, for example, to prepare nucleic acids that have altered base-pairing abilities or increased resistance to nucleases.

[0036] An isolated nucleic acid is a DNA or RNA that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. Thus, in one embodiment, an isolated nucleic acid includes some or all of the 5' non-coding (e.g., promoter) sequences that are immediately contiguous to the coding sequence. The term therefore includes, for example, a recombinant DNA that is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other sequences. It also includes a recombinant DNA that is part of a hybrid gene encoding an additional polypeptide sequence. The term "isolated" refers to a nucleic acid or polypeptide that is substantially free of cellular material, viral material, or culture medium (when produced by recombinant DNA techniques), or chemical precursors or other chemicals (when chemically synthesized). Moreover, an isolated nucleic acid fragment is a nucleic acid fragment that is not naturally occurring as a fragment and would not be found in the natural state.

[0037] A nucleic acid sequence that is substantially identical to an essential nucleotide sequence is at least 80% identical to the nucleotide sequence of NMT as represented by the SEQ ID NOs:1 and 3, as depicted in **FIGS. 1 and 2**. For purposes of comparison of nucleic acids, the length of the reference nucleic acid sequence will generally be at least 40 nucleotides, e.g., at least 60 nucleotides or more nucleotides.

[0038] To determine the percent identity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = # of identical positions/total # of overlapping positions × 100). Preferably, the two sequences are the same length.

[0039] The determination of percent homology between two sequences can be accomplished using a mathematical

algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) *Proc. Nat'l Acad. Sci. USA* 87:2264-2268, modified as in Karlin and Altschul (1993) *Proc. Nat'l Acad. Sci. USA* 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990) *J. Mol. Biol.* 215:403-410. BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to NMT nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to NMT protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) *Nucleic Acids Res.* 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>. Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.

[0040] The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, only exact matches are counted.

[0041] The NMT polypeptides of the invention include, but are not limited to, recombinant polypeptides and natural polypeptides. Also included are nucleic acid sequences that encode forms of NMT polypeptides in which naturally occurring amino acid sequences are altered or deleted. Preferred nucleic acids encode polypeptides that are soluble under normal physiological conditions. Also within the invention are nucleic acids encoding fusion proteins in which a portion of the NMT polypeptide is fused to an unrelated polypeptide (e.g., a marker polypeptide or a fusion partner) to create a fusion protein. For example, the polypeptide can be fused to a hexa-histidine tag to facilitate purification of bacterially expressed polypeptides, or to a hemagglutinin tag to facilitate purification of polypeptides expressed in eukaryotic cells. The invention also includes, for example, isolated polypeptides (and the nucleic acids that encode these polypeptides) that include a first portion and a second portion; the first portion includes, e.g., an NMT polypeptide, and the second portion includes an immunoglobulin constant (Fc) region or a detectable marker.

[0042] The fusion partner can be, for example, a polypeptide which facilitates secretion, e.g., a secretory sequence. Such a fused polypeptide is typically referred to as a preprotein. The secretory sequence can be cleaved by the host cell to form the mature protein. Also within the invention are nucleic acids that encode an essential polypeptide fused to a polypeptide sequence to produce an inactive preprotein. Preproteins can be converted into the active form of the protein by removal of the inactivating sequence.

[0043] The invention also includes nucleic acids that hybridize, e.g., under stringent hybridization conditions (as defined herein) to all or a portion of the nucleotide sequences represented by SEQ ID NO:1 or 3, or their complements. The hybridizing portion of the hybridizing nucleic acids is typically at least 15 (e.g., 20, 30, or 50) nucleotides in length. The hybridizing portion of the hybridizing nucleic acid is at least 60%, e.g., at least 70%, 80%, 95%, or at least 98%, identical to the sequence of a portion or all of a nucleic acid encoding an NMT polypeptide or its complement. Hybridizing nucleic acids of the type described herein can be used as a cloning probe, a primer (e.g., a PCR primer), or a diagnostic probe. Nucleic acids that hybridize to the nucleotide sequences represented by SEQ ID NOs: 1 and 3 are considered "antisense oligonucleotides."

[0044] Also useful in the invention are various engineered cells, e.g., transformed host cells, that contain an NMT nucleic acid described herein. A transformed cell is a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a nucleic acid encoding an essential polypeptide. Both prokaryotic and eukaryotic cells are included, e.g., fungi, and bacteria, such as *E. coli*, and the like.

[0045] Also useful in the invention are genetic constructs (e.g., vectors and plasmids) that include a nucleic acid of the invention which is operably linked to a transcription and/or translation sequence to enable expression, e.g., expression vectors. A selected nucleic acid, e.g., a DNA molecule encoding an NMT polypeptide, is "operably linked" when it is positioned adjacent to one or more sequence elements, e.g., a promoter, which direct transcription and/or translation of the sequence such that the sequence elements can control transcription and/or translation of the selected nucleic acid.

[0046] The invention also features purified or isolated polypeptides encoded by the *Aspergillus* NMT coding sequence. The terms "protein" and "polypeptide" both refer to any chain of amino acids, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation). Thus, the term NMT polypeptide includes full-length, naturally occurring, isolated NMT proteins, as well as recombinantly or synthetically produced polypeptides that correspond to the full-length, naturally occurring proteins, or to a portion of the naturally occurring or synthetic polypeptide.

[0047] A purified or isolated compound is a composition that is at least 60% by weight the compound of interest, e.g., an NMT polypeptide or antibody. Preferably the preparation is at least 75% (e.g., at least 90%, 95%, or even 99%) by weight the compound of interest. Purity can be measured by any appropriate standard method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

[0048] Preferred NMT polypeptides include a sequence substantially identical to all or a portion of a naturally occurring *Aspergillus* NMT polypeptide, e.g., including all or a portion of the sequences shown in FIG. 2. Polypeptides "substantially identical" to the NMT polypeptide sequences described herein have an amino acid sequence that is at least 65% identical to the amino acid sequence of the NMT polypeptide represented by the SEQ ID NO:2 (measured as described herein). The new polypeptides can also have a greater percentage identity, e.g., 85%, 90%, 95%, or even

higher. For purposes of comparison, the length of the reference NMT polypeptide sequence will generally be at least 16 amino acids, e.g., at least 20 or 25 amino acids.

[0049] In the case of polypeptide sequences that are less than 100% identical to a reference sequence, the non-identical positions are preferably, but not necessarily, conservative substitutions for the reference sequence. Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine.

[0050] Where a particular polypeptide is said to have a specific percent identity to a reference polypeptide of a defined length, the percent identity is relative to the reference polypeptide. Thus, a polypeptide that is 50% identical to a reference polypeptide that is 100 amino acids long can be a 50 amino acid polypeptide that is completely identical to a 50 amino acid long portion of the reference polypeptide. It also might be a 100 amino acid long polypeptide which is 50% identical to the reference polypeptide over its entire length. Of course, other polypeptides also will meet the same criteria.

[0051] The invention also features purified or isolated antibodies that specifically bind to an *Aspergillus* NMT polypeptide. An antibody "specifically binds" to a particular antigen, e.g., an NMT polypeptide, when it binds to that antigen, but does not substantially recognize and bind to other molecules in a sample, e.g., a biological sample, that naturally includes an NMT polypeptide. In addition, an antibody specifically binds to an *Aspergillus* NMT polypeptide when it does not substantially bind to NMT polypeptides from other genera (e.g., *Saccharomyces*, *Candida*), particularly NMT polypeptides of an organism to be treated by the methods of the invention (e.g., humans, or domesticated animals).

[0052] Identifying the *Aspergillus fumigatus* NMT Gene

[0053] As shown by the experiments described below, the *Aspergillus fumigatus* NMT gene is essential for survival. *Aspergillus fumigatus* is available from the ATCC. The *Aspergillus* NMT gene was cloned using polymerase chain reaction technology and degenerate primers based on the *Saccharomyces cerevisiae* and *Candida albicans* NMT genes. The degenerate primer termed degNMT-2 had the sequence: 5'RAN MAY TAY GTN GAR GA3' (SEQ ID NO:4) and the primer degNMT-4G had the sequence 5'CAN ARR AAR TTD ATY TCN AC3' (SEQ ID NO:5), where "R" represents adenine or guanine; "N" represents adenine, guanine, cytosine, or thymine; "Y" represents cytosine or thymine; and "D" represents adenine, thymine, or guanine. These degenerate primers were used to amplify genomic *Aspergillus fumigatus* DNA using 35 cycles of: 94° C. for 1 minute, 40° C. for 2 minutes, and 72° C. for 3 minutes. The resulting PCR product was subcloned into the pBluescript cloning vector (Stratagene; La Jolla, Calif.), then sequenced. Based on the resulting sequence, two exact-match primers were created: primer AfNMT-5 has the sequence 5'TGC CAT CTT CCG GTT CAG A3' (SEQ ID NO:6), and the primer AfNMT-7 has the sequence 5'TGC GCG ACT TCG TAG CGC GGA3' (SEQ ID NO:7). These primers were used to PCR amplify the 5' and 3' halves of the AfNMT from an *Aspergillus fumigatus* cDNA library. The cDNA library was

made using the vector pYES2 (Invitrogen; Palo Alto, Calif.). For PCR amplification, the AfNMT-5 primer was paired with a primer hybridizing to the 3' sequence of the multiple cloning site of pYES2. The AfNMT-7 primer was paired with a primer hybridizing to the pGAL sequences in pYES2. PCR amplification of the 5' and 3' halves of the NMT gene was carried out with 30 cycles of 94° C. for 30 seconds, 55° C. for 30 seconds, 720 for and 2.5 minutes. The resulting PCR products were cloned into the pBluescript vector and sequenced to obtain the cDNA sequence of *Aspergillus fumigatus* NMT. The entire NMT open reading frame was subsequently amplified using primers that exactly matched each of (a) the first methionine codon and (b) the stop codon of the NMT open reading frame. These primers were: AfNMT-N 5'CGC GCA TAT GGC GGA GTC GCT ATT GGA AAA CAA CCC CGC3' (SEQ ID NO:8) for the methionine codon and AfNMT-C: 5'GCA GCG GCC GCT TAC AGC ATA ACG ATG CCAACG CCT GCC3' (SEQ ID NO:9) for the stop codon. The amplified open reading frame subsequently was cloned into the pCRTPOPO vector (Invitrogen) using TA cloning methods (Invitrogen).

[0054] Identification of NMT Genes in Additional Fungal Strains

[0055] Now that the *Aspergillus fumigatus* NMT gene has been identified, this gene, or fragments thereof, can be used to detect homologous genes in yet other organisms. Fragments of a nucleic acid (DNA or RNA) encoding an NMT polypeptide (or sequences complementary thereto) can be used as probes in conventional nucleic acid hybridization assays of various organism. For example, nucleic acid probes (which typically are 8-30, or usually 15-20, nucleotides in length) can be used to detect NMT genes in art-known molecular biology methods, such as Southern blotting, Northern blotting, dot or slot blotting, PCR amplification methods, colony hybridization methods, and the like. Typically, an oligonucleotide probe based on the nucleic acid sequences described herein, or fragment thereof, is labeled and used to screen a genomic library constructed from mRNA obtained from a fungal strain of interest. A suitable method of labeling involves using polynucleotide kinase to add ³²P labeled ATP to the oligonucleotide used as the probe. This method is well known in the art, as are several other suitable methods (e.g., biotinylation and enzyme labeling).

[0056] Hybridization of the oligonucleotide probe to the library, or other nucleic acid sample, typically is performed under moderate to high stringency conditions. Nucleic acid duplex or hybrid stability is expressed as the melting temperature or T_m , which is the temperature at which a probe dissociates from a target DNA. This melting temperature is used to define the required stringency conditions. If sequences are to be identified that are related and substantially identical to the probe, rather than identical, then it is useful to first establish the lowest temperature at which only homologous hybridization occurs with a particular concentration of salt (e.g., SSC or SSPE). Then, assuming that 1% mismatching results in a 1° C. decrease in the T_m , the temperature of the final wash in the hybridization reaction is reduced accordingly (for example, if sequences having $\geq 95\%$ identity with the probe are sought, the final wash temperature is decreased by 5° C.). In practice, the change in T_m can be between 0.5° and 1.5° C. per 1% mismatch.

[0057] High stringency conditions include, for example, hybridizing at 68° C. in 5× SSC/5× Denhardt's solution/1.0% SDS, or in 0.5 M NaHPO₄ (pH 7.2)/1 mM EDTA/7% SDS, or in 50% formamide/0.25 M NaHPO₄ (pH 7.2)/0.25 M NaCl/1 mM EDTA/7% SDS; and washing in 0.2× SSC/0.1% SDS at room temperature or at 42° C., or in 0.1× SSC/0.1% SDS at 68° C., or in 40 mM NaHPO₄ (pH 7.2)/1 mM EDTA/5% SDS at 50° C., or in 40 mM NaHPO₄ (pH 7.2) 1 mM EDTA/1% SDS at 50° C. Moderately stringent conditions include washing in 3× SSC at 42° C. The parameters of salt concentration and temperature can be varied to achieve the optimal level of identity between the probe and the target nucleic acid. Additional guidance regarding such conditions is readily available in the art, for example, by Sambrook et al., 1989, *Molecular Cloning*, A Laboratory Manual, Cold Spring Harbor Press, N.Y.; and Ausubel et al. (eds.), 1995, *Current Protocols in Molecular Biology*, (John Wiley & Sons, N.Y.) at Unit 2.10.

[0058] In one approach, libraries constructed from pathogenic or non-pathogenic fungal strains can be screened. For example, such strains can be screened for expression of the NMT gene of the invention by Northern blot analysis. Upon detection of transcripts of the essential genes thereof, libraries can be constructed from RNA isolated from the appropriate strain, utilizing standard techniques well known to those of skill in the art. Alternatively, a total genomic DNA library can be screened using an NMT gene probe.

[0059] New gene sequences can be isolated, for example, by performing PCR using two degenerate oligonucleotide primer pools designed on the basis of nucleotide sequences within the NMT gene as depicted herein. The template for the reaction can be DNA obtained from strains known or suspected to express the NMT gene of the invention. The PCR product can be subcloned and sequenced.

[0060] Synthesis of the various NMT polypeptides (or an antigenic fragment thereof) for use as antigens, or for other purposes, can readily be accomplished using any of the various art-known techniques. For example, an NMT polypeptide, or an antigenic fragment(s), can be synthesized chemically in vitro, or enzymatically (e.g., by in vitro transcription and translation). Alternatively, the gene can be expressed in, and the polypeptide purified from, a cell (e.g., a cultured cell) by using any of the numerous, available gene expression systems. For example, the polypeptide antigen can be produced in a prokaryotic host (e.g., *E. coli*) or in eukaryotic cells, such as yeast cells.

[0061] Proteins and polypeptides can also be produced in plant cells, if desired. For plant cells, viral expression vectors (e.g., cauliflower mosaic virus and tobacco mosaic virus) and plasmid expression vectors (e.g., Ti plasmid) are suitable. Such cells are available from a wide range of sources (e.g., the American Type Culture Collection, Rockland, Md.; also, see, e.g., Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, 1994). The optimal methods of transformation or transfection and the choice of expression vehicle will depend on the host system selected. Transformation and transfection methods are described, e.g., in Ausubel et al., supra; expression vehicles may be chosen from those provided, e.g., in *Cloning Vectors: A Laboratory Manual* (P. H. Pouwels et al., 1985, Supp. 1987). The host cells harboring the expression vehicle can be cultured in conventional nutrient media,

adapted as needed for activation of a chosen gene, repression of a chosen gene, selection of transformants, or amplification of a chosen gene.

[0062] If desired, NMT polypeptide can be produced as a fusion protein. For example, the expression vector pUR278 (Ruther et al., *EMBO J.*, 2:1791, 1983) can be used to create lacZ fusion proteins. The art-known pGEX vectors can be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can be easily purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

[0063] In an exemplary expression system, a baculovirus such as *Autographa californica* nuclear polyhedrosis virus (AcNPV), which grows in *Spodoptera frugiperda* cells, can be used as a vector to express foreign genes. A coding sequence encoding an essential polypeptide can be cloned into a non-essential region (for example the polyhedrin gene) of the viral genome and placed under control of a promoter, e.g., the polyhedrin promoter or an exogenous promoter. Successful insertion of a gene encoding an essential polypeptide can result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat encoded by the polyhedrin gene). These recombinant viruses are then typically used to infect insect cells (e.g., *Spodoptera frugiperda* cells) in which the inserted gene is expressed (see, e.g., Smith et al., *J. Virol.*, 46:584, 1983; Smith, U.S. Pat. No. 4,215,051). If desired, mammalian cells can be used in lieu of insect cells, provided that the virus is engineered such that the gene encoding the NMT polypeptide is placed under the control of a promoter that is active in mammalian cells.

[0064] In mammalian host cells, a number of viral-based expression systems can be utilized. When an adenovirus is used as an expression vector, the nucleic acid sequence encoding the NMT polypeptide can be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene can then be inserted into the adenovirus genome by in vitro or in vivo recombination. Insertion into a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing an NMT gene product in infected hosts (see, e.g., Logan, *Proc. Natl. Acad. Sci. USA*, 81:3655, 1984).

[0065] Specific initiation signals may be required for efficient translation of inserted nucleic acid sequences. These signals include the ATG initiation codon and adjacent sequences. In general, exogenous translational control signals, including, perhaps, the ATG initiation codon, should be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire sequence. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, or transcription terminators (Bittner et al., *Methods in Enzymol.*, 153:516, 1987).

[0066] The NMT polypeptide can be expressed individually or as a fusion with a heterologous polypeptide, such as

a signal sequence or other polypeptide having a specific cleavage site at the N-and/or C-terminus of the protein or polypeptide. The heterologous signal sequence selected should be one that is recognized and processed, i.e., cleaved by a signal peptidase, by the host cell in which the fusion protein is expressed.

[0067] A host cell can be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in a specific, desired fashion. Such modifications and processing (e.g., cleavage) of protein products may facilitate optimal functioning of the protein. Various host cells have characteristic and specific mechanisms for post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems familiar to those of skill in the art of molecular biology can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, and phosphorylation of the gene product can be used. Such mammalian host cells include, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and choroid plexus cell lines.

[0068] If desired, the NMT polypeptide can be produced by a stably-transfected mammalian cell line. A number of vectors suitable for stable transfection of mammalian cells are available to the public, see, e.g., Pouwels et al. (supra); methods for constructing such cell lines are also publicly known, e.g., in Ausubel et al. (supra). In one example, DNA encoding the protein is cloned into an expression vector that includes the dihydrofolate reductase (DHFR) gene. Integration of the plasmid and, therefore, the essential polypeptide-encoding gene into the host cell chromosome is selected for by including 0.01-300 μ M methotrexate in the cell culture medium (as described in Ausubel et al., supra). This dominant selection can be accomplished in most cell types.

[0069] Recombinant protein expression can be increased by DHFR-mediated amplification of the transfected gene. Methods for selecting cell lines bearing gene amplifications are described in Ausubel et al. (supra); such methods generally involve extended culture in medium containing gradually increasing levels of methotrexate. DHFR-containing expression vectors commonly used for this purpose include pCVSEII-DHFR and pAdd26SV(A) (described in Ausubel et al., supra).

[0070] A number of other selection systems can be used, including but not limited to, herpes simplex virus thymidine kinase genes, hypoxanthine-guanine phosphoribosyl-transferase genes, and adenine phosphoribosyltransferase genes, which can be employed in tk, hgprt, or aprt cells, respectively. In addition, gpt, which confers resistance to mycophenolic acid (Mulligan et al., *Proc. Natl. Acad. Sci. USA*, 78:2072, 1981); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin et al., *J. Mol. Biol.*, 150:1, 1981); and hygromycin, which confers resistance to hygromycin (Santerre et al., *Gene*, 30:147, 1981), can be used.

[0071] Alternatively, any fusion protein can be readily purified by utilizing an antibody or other molecule that specifically binds the fusion protein being expressed. For example, a system described in Janknecht et al., *Proc. Natl. Acad. Sci. USA*, 88:8972 (1991), allows for the ready purification of non-denatured fusion proteins expressed in

human cell lines. In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni^{2+} nitriloacetic acid-agarose columns, and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

[0072] Alternatively, an NMT polypeptide, or a portion thereof, can be fused to an immunoglobulin Fc domain. Such a fusion protein can be readily purified using a protein A column, for example. Moreover, such fusion proteins permit the production of a chimeric form of an NMT polypeptide having increased stability *in vivo*.

[0073] Once the recombinant NMT polypeptide is expressed, it can be isolated (i.e., purified). Secreted forms of the polypeptides can be isolated from cell culture media, while non-secreted forms must be isolated from the host cells. Polypeptides can be isolated by affinity chromatography. For example, an anti-NMT antibody (e.g., produced as described herein) can be attached to a column and used to isolate the protein. Lysis and fractionation of cells harboring the protein prior to affinity chromatography can be performed by standard methods (see, e.g., Ausubel et al., *supra*). Alternatively, a fusion protein can be constructed and used to isolate an NMT polypeptide (e.g., a NMT-maltose binding fusion protein, a NMT- β -galactosidase fusion protein, or a NMT-trpE fusion protein; see, e.g., Ausubel et al., *supra*; New England Biolabs Catalog, Beverly, Mass.). The recombinant protein can, if desired, be further purified, e.g., by high performance liquid chromatography using standard techniques (see, e.g., Fisher, *Laboratory Techniques In Biochemistry And Molecular Biology*, eds., Work and Burdon, Elsevier, 1980).

[0074] Given the amino acid sequences described herein, polypeptides useful in practicing the invention, particularly fragments of essential polypeptides, can be produced by standard chemical synthesis (e.g., by the methods described in *Solid Phase Peptide Synthesis*, 2nd ed., The Pierce Chemical Co., Rockford, Ill., 1984) and used as antigens, for example.

[0075] Antibodies

[0076] The NMT polypeptides (or antigenic fragments or analogs of such polypeptides) can be used to raise antibodies useful in the invention, and such polypeptides can be produced by recombinant or peptide synthetic techniques (see, e.g., *Solid Phase Peptide Synthesis*, *supra*; Ausubel et al., *supra*). In general, the polypeptides can be coupled to a carrier protein, such as KLH, as described in Ausubel et al., *supra*, mixed with an adjuvant, and injected into a host mammal. A "carrier" is a substance that confers stability on, and/or aids or enhances the transport or immunogenicity of, an associated molecule. Antibodies can be purified, for example, by affinity chromatography methods in which the polypeptide antigen is immobilized on a resin.

[0077] In particular, various host animals can be immunized by injection of a polypeptide of interest. Examples of suitable host animals include rabbits, mice, guinea pigs, and rats. Various adjuvants can be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete adju-

vant), adjuvant mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

[0078] Antibodies useful in the invention include monoclonal antibodies, polyclonal antibodies, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')_2 fragments, and molecules produced using a Fab expression library.

[0079] Monoclonal antibodies (mAbs), which are homogeneous populations of antibodies to a particular antigen, can be prepared using NMT, and standard hybridoma technology (see, e.g., Kohler et al., *Nature*, 256:495, 1975; Kohler et al., *Eur. J. Immunol.*, 6:511, 1976; Kohler et al., *Eur. J. Immunol.*, 6:292, 1976; Hammerling et al., *In Monoclonal Antibodies and T Cell Hybridomas*, Elsevier, N.Y., 1981; Ausubel et al., *supra*).

[0080] In particular, monoclonal antibodies can be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture, such as those described in Kohler et al., *Nature*, 256:495, 1975, and U.S. Pat. No. 4,376,110; the human B-cell hybridoma technique (Kosbor et al., *Immunology Today*, 4:72, 1983; Cole et al., *Proc. Natl. Acad. Sci. USA*, 80:2026, 1983); and the EBV-hybridoma technique (Cole et al., *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96, 1983). Such antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD, and any subclass thereof. The hybridomas producing the mAbs of this invention can be cultivated *in vitro* or *in vivo*.

[0081] Once produced, polyclonal or monoclonal antibodies are tested for specific recognition of Aspergillus NMT in an immunoassay, such as a Western blot or immunoprecipitation analysis using standard techniques, e.g., as described in Ausubel et al., *supra*. Antibodies that specifically bind to the NMT polypeptide, or conservative variants are useful in the invention. For example, such antibodies can be used in an immunoassay to detect an NMT polypeptide in pathogenic or non-pathogenic strains of fungi.

[0082] Preferably, antibodies of the invention are produced using fragments of NMT that appear likely to be antigenic, by criteria such as high frequency of charged residues. In one specific example, such fragments are generated by standard techniques of PCR, and are then cloned into the pGEX expression vector (Ausubel et al., *supra*). Fusion proteins are expressed in *E. coli* and purified using a glutathione agarose affinity matrix as described in Ausubel et al., *supra*.

[0083] If desired, several (e.g., two or three) fusions can be generated for each protein, and each fusion can be injected into at least two rabbits. Antisera can be raised by injections in a series, typically including at least three booster injections. Typically, the antisera is checked for its ability to immunoprecipitate a recombinant essential polypeptide, or unrelated control proteins, such as glucocorticoid receptor, chloramphenicol acetyltransferase, or luciferase.

[0084] Techniques developed for the production of "chimeric antibodies" (Morrison et al., *Proc. Natl. Acad. Sci.*,

81:6851, 1984; Neuberger et al., *Nature*, 312:604, 1984; Takeda et al., *Nature*, 314:452, 1984) can be used to splice the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.

[0085] Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778; and U.S. Pat. Nos. 4,946,778 and 4,704,692) can be adapted to produce single chain antibodies against an NMT polypeptide. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

[0086] Antibody fragments that recognize and bind to specific epitopes can be generated by known techniques. For example, such fragments can include but are not limited to F(ab')₂ fragments, which can be produced by pepsin digestion of the antibody molecule, and Fab fragments, which can be generated by reducing the disulfide bridges of F(ab')₂ fragments. Alternatively, Fab expression libraries can be constructed (Huse et al., *Science*, 246:1275, 1989) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

[0087] Polyclonal and monoclonal antibodies that specifically bind to an NMT polypeptide can be used, for example, to detect expression of NMT in another strain of fungi. For example, an NMT polypeptide can be readily detected in conventional immunoassays of fungal cells or extracts. Examples of suitable assays include, without limitation, Western blotting, ELISAs, radioimmune assays, and the like.

[0088] Assay for Antifungal Agents

[0089] The invention provides a method for identifying an antifungal agent(s). Although the inventor is not bound by any particular theory as to the biological mechanism involved, the new antifungal agents are thought to inhibit specifically (1) the function of the NMT polypeptide or (2) expression of the NMT gene. In preferred methods, screening for antifungal agents is accomplished by identifying those compounds (e.g., small organic molecules) that inhibit the activity of an NMT polypeptide or the expression of an essential gene.

[0090] In an exemplary assay, but not the only assay, a promoter that responds to depletion of the essential polypeptide by upregulation or downregulation is linked to a reporter gene (e.g., β -galactosidase, gus, or GFP), as described above. A fungal strain containing this reporter gene construct is then exposed to test compounds. Compounds that inhibit the NMT (or other polypeptides in the pathway in which NMT participates) will cause a functional depletion of the NMT and therefore lead to an upregulation or downregulation of expression the reporter gene. Because NMT is essential for the survival of *Aspergillus*, compounds that inhibit the NMT in such an assay are expected to be antifungal agents and can be further tested, if desired, in conventional susceptibility assays.

[0091] In other suitable methods, screening for antifungal agents is accomplished by (i) identifying those compounds

that bind NMT and (ii) further testing such compounds for their ability to inhibit fungal growth in vitro or in vivo.

[0092] Specific binding of a test compound to a polypeptide can be detected, for example, in vitro by reversibly or irreversibly immobilizing the test compound(s) on a substrate, e.g., the surface of a well of a 96-well polystyrene microtitre plate. Methods for immobilizing polypeptides and other small molecules are well known in the art. For example, the microtitre plates can be coated with an NMT polypeptide by adding the polypeptide in a solution (typically, at a concentration of 0.05 to 1 mg/ml in a volume of 1-100 μ l) to each well, and incubating the plates at room temperature to 37° C. for 0.1 to 36 hours. Polypeptides that are not bound to the plate can be removed by shaking the excess solution from the plate, and then washing the plate (once or repeatedly) with water or a buffer. Typically, the polypeptide is in water or a buffer. The plate is then washed with a buffer that lacks the bound polypeptide. To block the free protein-binding sites on the plates, the plates are blocked with a protein that is unrelated to the bound polypeptide. For example, 300 μ l of bovine serum albumin (BSA) at a concentration of 2 mg/ml in Tris-HCl is suitable. Suitable substrates include those substrates that contain a defined cross-linking chemistry (e.g., plastic substrates, such as polystyrene, styrene, or polypropylene substrates from Corning Costar Corp. (Cambridge, Mass.), for example). If desired, a beaded particle, e.g., beaded agarose or beaded sepharose, can be used as the substrate.

[0093] Binding of the test compound to NMT can be detected by any of a variety of art-known methods. For example, an antibody that specifically binds an NMT polypeptide can be used in an immunoassay. If desired, the antibody can be labeled (e.g., fluorescently or with a radioisotope) and detected directly (see, e.g., West and McMahon, *J. Cell Biol.* 74:264, 1977). Alternatively, a second antibody can be used for detection (e.g., a labeled antibody that binds the Fc portion of an anti-YphC antibody). In an alternative detection method, the NMT polypeptide is labeled, and the label is detected (e.g., by labeling an essential polypeptide with a radioisotope, fluorophore, chromophore, or the like). In still another method, the NMT polypeptide is produced as a fusion protein with a protein that can be detected optically, e.g., green fluorescent protein (which can be detected under UV light). In an alternative method, the polypeptide can be produced as a fusion protein with an enzyme having a detectable enzymatic activity, such as horse radish peroxidase, alkaline phosphatase, β -galactosidase, or glucose oxidase. Genes encoding all of these enzymes have been cloned and are readily available for use by those of skill in the art. If desired, the fusion protein can include an antigen, and such an antigen can be detected and measured with a polyclonal or monoclonal antibody using conventional methods. Suitable antigens include enzymes (e.g., horse radish peroxidase, alkaline phosphatase, and β -galactosidase) and non-enzymatic polypeptides (e.g., serum proteins, such as BSA and globulins, and milk proteins, such as caseins).

[0094] In various in vivo methods for identifying polypeptides that bind NMT, the conventional two-hybrid assays of protein/protein interactions can be used (see e.g., Chien et al., *Proc. Natl. Acad. Sci. USA*, 88:9578, 1991; Fields et al., U.S. Pat. No. 5,283,173; Fields and Song, *Nature*, 340:245, 1989; Le Douarin et al., *Nucleic Acids Research*, 23:876,

1995; Vidal et al., *Proc. Natl. Acad. Sci. USA*, 93:10315-10320, 1996; and White, *Proc. Natl. Acad. Sci. USA*, 93:10001-10003, 1996). Generally, the two-hybrid methods involve in vivo reconstitution of two separable domains of a transcription factor. One fusion protein contains the NMT polypeptide fused to either a transactivator domain or DNA binding domain of a transcription factor (e.g., of Gal4). The other fusion protein contains a test polypeptide fused to either the DNA binding domain or a transactivator domain of a transcription factor. Once brought together in a single cell (e.g., a yeast cell or mammalian cell), one of the fusion proteins contains the transactivator domain and the other fusion protein contains the DNA binding domain. Therefore, binding of the NMT polypeptide to the test polypeptide (i.e., candidate antifungal agent) reconstitutes the transcription factor. Reconstitution of the transcription factor can be detected by detecting expression of a gene (i.e., a reporter gene) that is operably linked to a DNA sequence that is bound by the DNA binding domain of the transcription factor. Kits for practicing various two-hybrid methods are commercially available (e.g., from Clontech; Palo Alto, Calif.).

[0095] The methods described above can be used for high throughput screening of numerous test compounds to identify candidate antifungal (or anti-fungal) agents. Having identified a test compound as a candidate antifungal agent, the candidate antifungal agent can be further tested for inhibition of fungal growth in vitro or in vivo (e.g., using an animal, e.g., rodent, model system) if desired. Using other, art-known variations of such methods, one can test the ability of a nucleic acid (e.g., DNA or RNA) used as the test compound to bind NMT.

[0096] In vitro, further testing can be accomplished by means known to those in the art such as an enzyme inhibition assay or a whole-cell fungal growth inhibition assay. For example, an agar dilution assay identifies a substance that inhibits fungal growth. Microtiter plates are prepared with serial dilutions of the test compound, adding to the preparation a given amount of growth substrate, and providing a preparation of fungi. Inhibition of fungal growth is determined, for example, by observing changes in optical densities of the fungal cultures.

[0097] Inhibition of fungal growth is demonstrated, for example, by comparing (in the presence and absence of a test compound) the rate of growth or the absolute growth of fungal cells. Inhibition includes a reduction of one of the above measurements by at least 20%. Particularly potent test compounds may further reduce the growth rate (e.g., by at least 25%, 30%, 40%, 50%, 75%, 80%, or 90%).

[0098] Animal (e.g., rodent such as murine) models of fungal infections are known to those of skill in the art, and such animal model systems are accepted for screening antifungal agents as an indication of their therapeutic efficacy in human patients. In a typical in vivo assay, an animal is infected with a pathogenic strain of fungi, e.g., by inhalation of fungi, and conventional methods and criteria are used to diagnose the mammal as being afflicted with a fungal infection. The candidate antifungal agent then is administered to the mammal at a dosage of 1-100 mg/kg of body weight, and the mammal is monitored for signs of amelioration of disease. Alternatively, the test compound can be administered to the mammal prior to infecting the mammal

with the fungi, and the ability of the treated mammal to resist infection is measured. Of course, the results obtained in the presence of the test compound should be compared with results in control animals, which are not treated with the test compound. Administration of candidate antifungal agents to the mammal can be carried out as described below, for example.

[0099] Pharmaceutical Formulations

[0100] Treatment includes administering a pharmaceutically effective amount of a composition containing an antifungal agent to a subject in need of such treatment, thereby inhibiting fungal growth in the subject. Such a composition typically contains from about 0.1 to 90% by weight (such as 1 to 20% or 1 to 10%) of an antifungal agent of the invention in a pharmaceutically acceptable carrier.

[0101] Solid formulations of the compositions for oral administration may contain suitable carriers or excipients, such as corn starch, gelatin, lactose, acacia, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, calcium carbonate, sodium chloride, or alginic acid. Disintegrators that can be used include, without limitation, microcrystalline cellulose, corn starch, sodium starch glycolate and alginic acid. Tablet binders that may be used include acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Povidone), hydroxypropyl methylcellulose, sucrose, starch, and ethylcellulose. Lubricants that may be used include magnesium stearates, stearic acid, silicone fluid, talc, waxes, oils, and colloidal silica.

[0102] Liquid formulations of the compositions for oral administration prepared in water or other aqueous vehicles may contain various suspending agents such as methylcellulose, alginates, tragacanth, pectin, kelgin, carrageenan, acacia, polyvinylpyrrolidone, and polyvinyl alcohol. The liquid formulations may also include solutions, emulsions, syrups and elixirs containing, together with the active compound(s), wetting agents, sweeteners, and coloring and flavoring agents. Various liquid and powder formulations can be prepared by conventional methods for inhalation into the lungs of the mammal to be treated.

[0103] Injectable formulations of the compositions may contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like). For intravenous injections, water soluble versions of the compounds may be administered by the drip method, whereby a pharmaceutical formulation containing the antifungal agent and a physiologically acceptable excipient is infused. Physiologically acceptable excipients may include, for example, 5% dextrose, 0.9% saline, Ringer's solution or other suitable excipients. Intramuscular preparations, a sterile formulation of a suitable soluble salt form of the compounds can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution. A suitable insoluble form of the compound may be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, such as an ester of a long chain fatty acid, (e.g., ethyl oleate).

[0104] A topical semi-solid ointment formulation typically contains a concentration of the active ingredient from about 1 to 20%, e.g., 5 to 10% in a carrier such as a pharmaceutical

cream base. Various formulations for topical use include drops, tinctures, lotions, creams, solutions, and ointments containing the active ingredient and various supports and vehicles.

[0105] The optimal percentage of the antifungal agent in each pharmaceutical formulation varies according to the formulation itself and the therapeutic effect desired in the specific pathologies and correlated therapeutic regimens. Appropriate dosages of the antifungal agents can be readily determined by those of ordinary skill in the art of medicine by monitoring the mammal for signs of disease amelioration or inhibition, and increasing or decreasing the dosage and/or frequency of treatment as desired. The optimal amount of the antifungal compound used for treatment of conditions caused by or contributed to by fungal infection may depend upon the manner of administration, the age and the body weight of the subject, and the condition of the subject to be treated. Generally, the antifungal compound is administered

at a dosage of 1 to 100 mg/kg of body weight, and typically at a dosage of -1 to 10 mg/kg of body weight.

OTHER EMBODIMENTS

[0106] It is to be understood that, while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. For example, other art-known assays to detect interactions of test compounds with proteins, or to detect inhibition of fungal growth also can be used with the NMT gene. The invention also includes methods of making a pharmaceutical composition for use in inhibiting *Aspergillus*. Specifically, the method includes formulating a pharmaceutically acceptable excipient with an antifungal agent, such as those described herein

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 10

<210> SEQ ID NO 1

<211> LENGTH: 1392

<212> TYPE: DNA

<213> ORGANISM: *Aspergillus fumigatus* N-myristoyl

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)...(1389)

<400> SEQUENCE: 1

atg gcg gag tcg cta ttg gaa aac aac ccc gct ctc agg aac gag acg	48
Met Ala Glu Ser Leu Leu Glu Asn Asn Pro Ala Leu Arg Asn Glu Thr	
1 5 10 15	
gcc ggc atg gac aaa gac aag gcg gcg gag gca atg cgc aaa atg aac	96
Ala Gly Met Asp Lys Asp Lys Ala Ala Glu Ala Met Arg Lys Met Asn	
20 25 30	
att gcc gaa ttg ctg aca ggc ttg tca gtt tcc ggg aag aac cag aag	144
Ile Ala Glu Leu Leu Thr Gly Leu Ser Val Ser Gly Lys Asn Gln Lys	
35 40 45	
gat atg gct tcg tac aag ttt tgg caa acg cag cct gtg ccc cga ttc	192
Asp Met Ala Ser Tyr Lys Phe Trp Gln Thr Gln Pro Val Pro Arg Phe	
50 55 60	
gat gag acg agt acc gat act ggg ggc cct atc aag atc att gat cct	240
Asp Glu Thr Ser Thr Asp Thr Gly Gly Pro Ile Lys Ile Ile Asp Pro	
65 70 75 80	
gaa aag gtc tca aag gaa ccg gat gcg ctg ctt gaa gga ttt gaa tgg	288
Glu Lys Val Ser Lys Glu Pro Asp Ala Leu Leu Glu Gly Phe Glu Trp	
85 90 95	
gcg aca ctc gac ctg aca aac gag act gag ctg cag gag ctg tgg gat	336
Ala Thr Leu Asp Leu Thr Asn Glu Thr Glu Leu Gln Glu Leu Trp Asp	
100 105 110	
ttg ttg acg tat cac tac gta gag gac gac aat gcc atg ttc cgg ttc	384
Leu Leu Thr Tyr His Tyr Val Glu Asp Asp Asn Ala Met Phe Arg Phe	
115 120 125	
aga tat tcg cag tcg ttc cta cac tgg gct ctt atg tcg cct gcc tgg	432
Arg Tyr Ser Gln Ser Phe Leu His Trp Ala Leu Met Ser Pro Gly Trp	
130 135 140	
aaa aag gaa tgg cat gtc ggt gtc cgc gct acg aag tcg cgc aaa ctg	480

-continued

Lys 145	Lys	Glu	Trp	His	Val 150	Gly	Val	Arg	Ala	Thr 155	Lys	Ser	Arg	Lys	Leu 160	
gta	gcg	tcc	att	tgc	ggt	gtc	ccg	aca	gag	atc	aat	gtg	cgc	aat	caa	528
Val	Ala	Ser	Ile	Cys	Gly	Val	Pro	Thr	Glu	Ile	Asn	Val	Arg	Asn	Gln	
				165					170					175		
aag	ctc	aag	gtc	gtc	gag	atc	aat	ttc	ctc	tgc	atc	cac	aag	aag	ctc	576
Lys	Leu	Lys	Val	Val	Glu	Ile	Asn	Phe	Leu	Cys	Ile	His	Lys	Lys	Leu	
			180					185					190			
cgc	tcg	aag	cgc	ttg	acc	cca	gtt	ctc	atc	aaa	gaa	atc	acc	cg	cg	624
Arg	Ser	Lys	Arg	Leu	Thr	Pro	Val	Leu	Ile	Lys	Glu	Ile	Thr	Arg	Arg	
			195				200					205				
tgc	tac	ctc	aat	ggc	atc	tac	caa	gcc	atc	tac	act	gcg	ggt	gtg	gtg	672
Cys	Tyr	Leu	Asn	Gly	Ile	Tyr	Gln	Ala	Ile	Tyr	Thr	Ala	Gly	Val	Val	
	210				215					220						
ctc	ccc	act	cct	gtc	agc	tca	tgc	cg	tac	tac	cac	cg	cct	ttg	gac	720
Leu	Pro	Thr	Pro	Val	Ser	Ser	Cys	Arg	Tyr	Tyr	His	Arg	Pro	Leu	Asp	
	225				230				235					240		
tgg	ttg	aag	ctt	tac	gag	gtc	ggc	ttc	tcg	cct	ctc	cct	gcc	gga	tcc	768
Trp	Leu	Lys	Leu	Tyr	Glu	Val	Gly	Phe	Ser	Pro	Leu	Pro	Ala	Gly	Ser	
				245					250					255		
acc	aag	gcg	cg	cag	atc	acc	aag	aat	cac	ctg	ccc	agt	act	acc	tct	816
Thr	Lys	Ala	Arg	Gln	Ile	Thr	Lys	Asn	His	Leu	Pro	Ser	Thr	Thr	Ser	
			260					265					270			
acc	ccc	ggt	ctt	cg	ccc	atg	gag	ccc	aaa	gac	att	gac	aca	gtg	cat	864
Thr	Pro	Gly	Leu	Arg	Pro	Met	Glu	Pro	Lys	Asp	Ile	Asp	Thr	Val	His	
		275				280					285					
gat	ctt	ttg	cag	cga	tac	ttg	tcg	cg	ttt	gcg	ttg	aac	cag	gcc	ttt	912
Asp	Leu	Leu	Gln	Arg	Tyr	Leu	Ser	Arg	Phe	Ala	Leu	Asn	Gln	Ala	Phe	
	290					295					300					
acg	cga	gag	gaa	gtg	gac	cat	tgg	ctc	gtg	cac	aag	ccg	gag	acg	gtg	960
Thr	Arg	Glu	Glu	Val	Asp	His	Trp	Leu	Val	His	Lys	Pro	Glu	Thr	Val	
	305			310					315					320		
aaa	gag	cag	gtc	gtc	tgg	gca	tac	gtg	gta	gag	gac	cct	gaa	acg	cac	1008
Lys	Glu	Gln	Val	Val	Trp	Ala	Tyr	Val	Val	Glu	Asp	Pro	Glu	Thr	His	
			325					330						335		
aag	atc	acc	gac	ttc	ttt	tcc	ttc	tac	aac	ctc	gaa	tcc	acc	gtc	att	1056
Lys	Ile	Thr	Asp	Phe	Phe	Ser	Phe	Tyr	Asn	Leu	Glu	Ser	Thr	Val	Ile	
			340					345					350			
cag	aat	ccc	aag	cat	gac	aat	gtg	cg	gct	gct	tac	ctg	tac	tac	tat	1104
Gln	Asn	Pro	Lys	His	Asp	Asn	Val	Arg	Ala	Ala	Tyr	Leu	Tyr	Tyr	Tyr	
		355				360					365					
gca	acc	gaa	aca	gct	ttc	acc	aat	aac	atg	aag	gct	ctc	aaa	gag	cg	1152
Ala	Thr	Glu	Thr	Ala	Phe	Thr	Asn	Asn	Met	Lys	Ala	Leu	Lys	Glu	Arg	
		370				375					380					
ctg	ctg	atg	ctg	atg	aat	gac	gct	ctg	atc	ctg	gct	aag	aag	gcg	cac	1200
Leu	Leu	Met	Leu	Met	Asn	Asp	Ala	Leu	Ile	Leu	Ala	Lys	Lys	Ala	His	
		385			390					395				400		
ttt	gat	gtg	ttc	aac	gca	ctt	acg	ctt	cac	gat	aac	cct	ctg	ttc	ctc	1248
Phe	Asp	Val	Phe	Asn	Ala	Leu	Thr	Leu	His	Asp	Asn	Pro	Leu	Phe	Leu	
			405					410						415		
gaa	caa	ctc	aaa	ttt	gga	gct	ggc	gat	ggg	cag	ctt	cac	ttc	tac	ctc	1296
Glu	Gln	Leu	Lys	Phe	Gly	Ala	Gly	Asp	Gly	Gln	Leu	His	Phe	Tyr	Leu	
			420					425					430			
tac	aac	tat	cg	acc	gcc	cct	gtt	cct	gga	gga	gtt	aac	gag	aag	aac	1344
Tyr	Asn	Tyr	Arg	Thr	Ala	Pro	Val	Pro	Gly	Gly	Val	Asn	Glu	Lys	Asn	
		435				440						445				
ctg	ccg	gat	gag	aaa	aga	atg	gga	ggc	gtt	ggc	atc	gtt	atg	ctg		1389

-continued

Leu Pro Asp Glu Lys Arg Met Gly Gly Val Gly Ile Val Met Leu
450 455 460

taa

1392

<210> SEQ ID NO 2

<211> LENGTH: 463

<212> TYPE: PRT

<213> ORGANISM: Aspergillus fumigatus N-myristoyl

<400> SEQUENCE: 2

Met Ala Glu Ser Leu Leu Glu Asn Asn Pro Ala Leu Arg Asn Glu Thr
1 5 10 15Ala Gly Met Asp Lys Asp Lys Ala Ala Glu Ala Met Arg Lys Met Asn
20 25 30Ile Ala Glu Leu Leu Thr Gly Leu Ser Val Ser Gly Lys Asn Gln Lys
35 40 45Asp Met Ala Ser Tyr Lys Phe Trp Gln Thr Gln Pro Val Pro Arg Phe
50 55 60Asp Glu Thr Ser Thr Asp Thr Gly Gly Pro Ile Lys Ile Ile Asp Pro
65 70 75 80Glu Lys Val Ser Lys Glu Pro Asp Ala Leu Leu Glu Gly Phe Glu Trp
85 90 95Ala Thr Leu Asp Leu Thr Asn Glu Thr Glu Leu Gln Glu Leu Trp Asp
100 105 110Leu Leu Thr Tyr His Tyr Val Glu Asp Asp Asn Ala Met Phe Arg Phe
115 120 125Arg Tyr Ser Gln Ser Phe Leu His Trp Ala Leu Met Ser Pro Gly Trp
130 135 140Lys Lys Glu Trp His Val Gly Val Arg Ala Thr Lys Ser Arg Lys Leu
145 150 155 160Val Ala Ser Ile Cys Gly Val Pro Thr Glu Ile Asn Val Arg Asn Gln
165 170 175Lys Leu Lys Val Val Glu Ile Asn Phe Leu Cys Ile His Lys Lys Leu
180 185 190Arg Ser Lys Arg Leu Thr Pro Val Leu Ile Lys Glu Ile Thr Arg Arg
195 200 205Cys Tyr Leu Asn Gly Ile Tyr Gln Ala Ile Tyr Thr Ala Gly Val Val
210 215 220Leu Pro Thr Pro Val Ser Ser Cys Arg Tyr Tyr His Arg Pro Leu Asp
225 230 235 240Trp Leu Lys Leu Tyr Glu Val Gly Phe Ser Pro Leu Pro Ala Gly Ser
245 250 255Thr Lys Ala Arg Gln Ile Thr Lys Asn His Leu Pro Ser Thr Thr Ser
260 265 270Thr Pro Gly Leu Arg Pro Met Glu Pro Lys Asp Ile Asp Thr Val His
275 280 285Asp Leu Leu Gln Arg Tyr Leu Ser Arg Phe Ala Leu Asn Gln Ala Phe
290 295 300Thr Arg Glu Glu Val Asp His Trp Leu Val His Lys Pro Glu Thr Val
305 310 315 320Lys Glu Gln Val Val Trp Ala Tyr Val Val Glu Asp Pro Glu Thr His
325 330 335

-continued

Lys Ile Thr Asp Phe Phe Ser Phe Tyr Asn Leu Glu Ser Thr Val Ile
 340 345 350
 Gln Asn Pro Lys His Asp Asn Val Arg Ala Ala Tyr Leu Tyr Tyr Tyr
 355 360 365
 Ala Thr Glu Thr Ala Phe Thr Asn Asn Met Lys Ala Leu Lys Glu Arg
 370 375 380
 Leu Leu Met Leu Met Asn Asp Ala Leu Ile Leu Ala Lys Lys Ala His
 385 390 395 400
 Phe Asp Val Phe Asn Ala Leu Thr Leu His Asp Asn Pro Leu Phe Leu
 405 410 415
 Glu Gln Leu Lys Phe Gly Ala Gly Asp Gly Gln Leu His Phe Tyr Leu
 420 425 430
 Tyr Asn Tyr Arg Thr Ala Pro Val Pro Gly Gly Val Asn Glu Lys Asn
 435 440 445
 Leu Pro Asp Glu Lys Arg Met Gly Gly Val Gly Ile Val Met Leu
 450 455 460

<210> SEQ ID NO 3

<211> LENGTH: 1735

<212> TYPE: DNA

<213> ORGANISM: Aspergillus fumigatus N-myristoyl

<400> SEQUENCE: 3

```

tccgactcta aggatcgcaa gggcaaggcc cccgagggcc agtcttccga aaagaaagat      60
ggcgcggtga acataacccc tcagatggcg gagtcgctat tggaaaacaa ccccgcctctc    120
aggaacgaga cggccggcat ggacaagac aaggcggcgg aggcaatgcg caaatgaac      180
attgccgaat tgctgacagg cttgtcagtt tccgggaaga accagaagga tatggcttcg    240
tacaagtttt ggcaaacgca gcctgtgccc cgattcgatg agacgagtac cgatactggg    300
ggccctatca agatcattga tcctgaaaag gtctcaaagg aaccggatgc gctgcttgaa    360
ggatttgaat gggcgacact cgacctgaca aacgagactg agctgcagga gctgtgggat    420
ttgttgacgt atcactacgt agaggacgac aatgccatgt tccggttcag atattcgag      480
tcgttcctac actggtgggt gcacaacgcg gccgagggat ctgtttctca ccggcttggg    540
aggggttgga ttatttgagc gctgacaatt ttgaccgtag ggctcttatg tcgcctggct    600
ggaaaaagga atggcatgtc ggtgtccgcg ctacgaagtc gcgcaaaactg gtagcgcca      660
tttgcggtgt cccgacagag atcaatgtgc gcaatcaaaa gctcaaggtc gtcgagatca    720
atttcctctg catccacaag aagctccgct cgaagcgctt gaccccgatt ctcatcaaag    780
aaatcacccg tcgttgctac ctcaatggca tctaccaagc catctacact gcgggtgttg      840
tgctccccac tcctgtcagc tcatgccgct actaccaccg tcctttggac tggttgaagc    900
tttacgaggt cggtctctcg cctctccctg ccggatccac caaggcgcgc cagatcacca    960
agaatcacct gccagtaact acctctaccc ccggtcttcg ccccatggag cccaaagaca   1020
ttgacacagt gcatgatcct ttgcagcgat acttgtcgcg gtttgcggtg aaccaggcct   1080
ttacgcgaga ggaagtggac cattggctcg tgcacaagcc ggagacgggtg aaagagcagg   1140
tcgtctgggc atacgtggta gaggaccctg aaacgcacaa gatcaccgac ttcttttcct   1200
tctacaacct cgaatccacc gtcattcaga atcccaagca tgacaatgtg cgtgctgctt   1260
acctgtacta ctatgcaacc gaaacagctt tcaccaataa catgaaggct ctcaaagagc   1320

```

-continued

gtctgctgat gctgatgaat gacgctctga tcctggctaa gaaggtaact acagggatcc	1380
actgccattt ccctggagtt gacttacgaa gctgacattg tgttgatagg cgcactttga	1440
tgtgttcaac gcacttacgc ttcacgataa ccctctgttc ctcgaacaac tcaaatttgg	1500
agctggcgat gggcagcttc acttctacct ctacaactat cgcaccgccc ctgttcctgg	1560
aggagttaac gagaagaacc tgccggatga gaaaagaatg ggaggcggtg gcacggttat	1620
gctgtaaaaa attctcaccg catggaccat gcctctcgcc tcgttgatga tcgcatctta	1680
tacctatttc tcgctgtgac atgaatttgg gtatgcgaaa taccatgaaa atttg	1735

<210> SEQ ID NO 4
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Aspergillus fumigatus N-myristoyl
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)...(17)
<223> OTHER INFORMATION: n = A,T,C or G

<400> SEQUENCE: 4

ranmaytayg tngarga	17
--------------------	----

<210> SEQ ID NO 5
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Aspergillus fumigatus N-myristoyl
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)...(20)
<223> OTHER INFORMATION: n = A,T,C or G

<400> SEQUENCE: 5

canarraart tdatytcnac	20
-----------------------	----

<210> SEQ ID NO 6
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Aspergillus fumigatus N-myristoyl

<400> SEQUENCE: 6

tgccatcttc cggttcaga	19
----------------------	----

<210> SEQ ID NO 7
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Aspergillus fumigatus N-myristoyl

<400> SEQUENCE: 7

tgcgcgactt cgtaggcggg a	21
-------------------------	----

<210> SEQ ID NO 8
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Aspergillus fumigatus N-myristoyl

<400> SEQUENCE: 8

cgcgcatatg gcggagtcgc tattggaaaa caaccccg	39
---	----

<210> SEQ ID NO 9
<211> LENGTH: 39
<212> TYPE: DNA

-continued

<213> ORGANISM: *Aspergillus fumigatus* N-myristoyl

<400> SEQUENCE: 9

gcagcgggcg cttacagcat aacgatgcc aagcctgcc 39

<210> SEQ ID NO 10

<211> LENGTH: 1735

<212> TYPE: DNA

<213> ORGANISM: *Aspergillus fumigatus* N-myristoyl

<400> SEQUENCE: 10

aggctgagat tcctagcgtt cccgttccgg gggctcccgg tcagaaggct tttctttcta	60
ccgcgccact tgtattgggg agtctaccgc ctacgcgata accttttggt gggcgagag	120
tccttgcctt gccggccgta cctgtttctg ttccgccgcc tccgttacgc gttttacttg	180
taacggctta acgactgtcc gaacagtcaa aggccttctt tggctcttct ataccgaagc	240
atgttcaaaa ccgtttgcgt cggacacggg gctaagctac tctgctcatg gctatgacct	300
ccgggtagat tctagtaact aggacttttc cagagtttcc ttggcctacg cgacgaactt	360
cctaaactta cccgctgtga gctggactgt ttgctctgac tcgacgtcct cgacacccta	420
aacaactgca tagtgatgca tctcctgctg ttacgggtaca aggccaaagtc tataagcgtc	480
agcaaggatg tgaccaccca cgtgttgccg cggctcccta gacaaagagt ggcgaaccca	540
tcccacacct aataaactcg cgactgttaa aactggcctc ccgagaatac agcggaccga	600
ccttttttct taccgtacag ccacaggcgc gatgcttcag cgcgtttgac catcgagggt	660
aaacgccaca gggctgtctc tagttacacg cgtaggtttt cgagttccag cagctctagt	720
taaaggagag gtaggtgttc ttcgaggcga gcttcgcgaa ctgggggtcaa gtagtagttc	780
tttagtgggc agcaacgatg gagttaccgt agatgggtcg gtagatgtga cggccacacc	840
acgaggggtg aggacagtcg agtacggcga tgatgggtgg aggaaacctg accaacttcg	900
aaatgctcca gccgaagagc ggagagggac ggcctagggt gttccgcgcg gcttagtggt	960
tccttagtga cgggtcatga tggagatggg ggccagaagc ggggtacctc gggtttctgt	1020
aactgtgtca cgtactagaa aacgtcgcta tgaacagcgc caaacgcaac ttggtccgga	1080
aatgcgctct ccttcacctg gtaaccgagc acgtgttcgg cctctgccac tttctcgtcc	1140
agcagaccct tatgcacctc ctccctggac tttgcgtggt ctagtggctg aagaaaagga	1200
agatgttgga gcttaggtgg cagtaagtct tagggttcgt actgttacac gcacgacgaa	1260
tggacatgat gatacgttgg ctttgcgaa agtgggtatt gtacttccga gagtttctcg	1320
cagacgacta cgactactta cagcgagact aggaccgatt cttccattga tgcctctagg	1380
tgacggtaaa gggacctcaa ctgaatgctt cgactgtaac acaactatcc gcgtgaaact	1440
acacaagttg cgtgaatgag aagtgtctatt gggagacaag gagctgtgtg agtttaaac	1500
tcgaccgcta cccgtcgaag tgaagatgga gatgttgata gcgtggcggg gacaaggacc	1560
tcctcaattg ctcttcttgg acggcctact cttttcttac cctccgcaac cgtagcaata	1620
cgacattttg taagagtggc gtacctggta cggagagcgg agcaactact agcgtagaat	1680
atggataaag agcgacactg tacttaaac cctacgcttt atgggtacttt taaac	1735

What is claimed is:

1. An isolated nucleic acid molecule encoding an NMT polypeptide comprising the amino acid sequence of SEQ ID NO:2, as depicted in **FIG. 1**.

2. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:

(1) the sequence of SEQ ID NO:1, as depicted in **FIG. 1**, or degenerate variants thereof;

(2) the sequence of SEQ ID NO:1, or degenerate variants thereof, wherein T is replaced by U;

(3) nucleic acid sequences complementary to sequences of (1) and (2);

(4) nucleic acid fragments of sequences of (1), (2), and (3) that are at least 15 base pairs in length and which hybridize under stringent conditions to genomic DNA encoding the polypeptide of SEQ ID NO:2;

(5) the sequence of SEQ ID NO:3, as depicted in **FIG. 2**, or degenerate variants thereof;

(6) the sequence of SEQ ID NO:3, or degenerate variants thereof, wherein T is replaced by U;

(7) nucleic acid sequences complementary to sequences of (5) and (6); and

(8) nucleic acid fragments of sequences of (5), (6), and (7) that are at least 15 base pairs in length and that hybridize under stringent conditions to genomic DNA encoding the polypeptide of SEQ ID NO:2.

3. An isolated nucleic acid molecule from *Aspergillus* that is at least 85% identical to SEQ ID NO:1 or SEQ ID NO:3.

4. An isolated nucleic acid molecule that is at least 15 base pairs in length and hybridizes under stringent conditions to SEQ ID NO:1 or SEQ ID NO:3.

5. A vector comprising a nucleic acid molecule of claim 1.

6. A vector comprising a nucleic acid molecule of claim 2.

7. An expression vector comprising a nucleic acid molecule of claim 1 operably linked to a nucleotide sequence regulatory element that controls expression of said nucleic acid molecule.

8. An expression vector comprising a nucleic acid molecule of claim 2, wherein said nucleic acid molecule is operably linked to a nucleotide sequence regulatory element that controls expression of said nucleic acid molecule.

9. A host cell comprising an exogenously introduced nucleic acid molecule of claim 1.

10. A host cell comprising an exogenously introduced nucleic acid molecule of claim 2.

11. A host cell of claim 9, wherein the cell is a fungus, yeast, or bacterium.

12. A host cell of claim 10, wherein the cell is a fungus, yeast, or bacterium.

13. A genetically engineered host cell comprising a nucleic acid molecule of claim 1 operably linked to a heterologous nucleotide sequence regulatory element that controls expression of the nucleic acid molecule in the host cell.

14. A host cell of claim 13, wherein the cell is a fungus, yeast or bacterium.

15. A genetically engineered host cell comprising a nucleic acid molecule of claim 2 operably linked to a

nucleotide sequence regulatory element that controls expression of the nucleic acid in the host cell.

16. A host cell of claim 15, wherein the cell is a fungus, yeast or bacterium.

17. An isolated polypeptide encoded by a nucleic acid having the sequence of SEQ ID NO:1 or SEQ ID NO:3.

18. An isolated polypeptide encoded by a nucleic acid molecule of claim 1.

19. An isolated polypeptide encoded by a nucleic acid molecule of claim 2.

20. An isolated polypeptide encoded by a nucleic acid molecule of claim 3.

21. A method for identifying an antifungal agent, the method comprising:

(a) contacting an NMT polypeptide with a test compound; and

(b) detecting binding of the test compound to the NMT polypeptide, wherein binding indicates that the test compound is an antifungal agent.

22. A method of claim 21, further comprising:

(c) determining whether a test compound that binds to the polypeptide inhibits growth of fungi, relative to growth of fungi cultured in the absence of a test compound that binds to the polypeptide, wherein inhibition of growth indicates that the test compound is an antifungal agent.

23. A method of claim 21, wherein the polypeptide is derived from a non-pathogenic *Aspergillus* strain.

24. A method of claim 21, wherein the polypeptide is derived from a pathogenic *Aspergillus* strain.

25. A method of claim 21, wherein the test compound is immobilized on a substrate, and binding of the test compound to the polypeptide is detected as immobilization of the polypeptide on the immobilized test compound.

26. A method of claim 21, wherein the test compound is selected from the group consisting of polypeptides, ribonucleic acids, small molecules, and deoxyribonucleic acids.

27. A pharmaceutical formulation comprising an antifungal agent identified by the method of claim 21, and a pharmaceutically acceptable excipient.

28. A method for treating a fungal infection in an organism, the method comprising administering to the organism a therapeutically effective amount of the pharmaceutical formulation of claim 27.

29. A pharmaceutical formulation comprising an antifungal agent identified by the method of claim 24, and a pharmaceutically acceptable excipient.

30. A method for treating an *Aspergillus* infection in an organism, the method comprising administering to the organism a therapeutically effective amount of the pharmaceutical formulation of claim 27.

31. The method of claim 30, wherein the organism is a human or rodent.

32. An antibody that specifically binds to a polypeptide of claim 18.

33. An antibody of claim 32, wherein the antibody is a monoclonal antibody.

34. A method for identifying an antifungal agent, the method comprising:

(a) contacting an NMT polypeptide with a test compound;

(b) detecting a decrease in function of the polypeptide contacted with the test compound; and

- (c) determining whether a test compound that decreases function of a contacted polypeptide inhibits growth of fungi, relative to growth of fungi cultured in the absence of a test compound that decreases function of a contacted polypeptide, wherein inhibition of growth indicates that the test compound is an antifungal agent.

35. A method of claim 34, wherein the test compound is selected from the group consisting of polypeptides, ribonucleic acids, small molecules, and deoxyribonucleic acids.

36. The method of claim 34, wherein the function is attachment of myristate to an amino-terminal glycine of a polypeptide.

37. A method for identifying an antifungal agent, the method comprising:

- (a) contacting a nucleic acid encoding *Aspergillus* NMT with a test compound; and
- (b) detecting binding of the test compound to the nucleic acid, wherein binding indicates that the test compound is an antifungal agent.

38. A method of claim 37, further comprising:

- (c) determining whether a test compound that binds to the nucleic acid inhibits growth of fungi, relative to growth of fungi cultured in the absence of the test compound that binds the nucleic acid, wherein inhibition of growth indicates that the test compound is an antifungal agent.

39. A method of claim 37, wherein the test compound is selected from the group consisting of polypeptides, small molecules, ribonucleic acids, and deoxyribonucleic acids.

40. An isolated nucleic acid molecule, said molecule comprising the cDNA sequence contained within an American Type Culture Collection (ATCC) accession number

41. A polypeptide encoded by the cDNA sequence of the isolated nucleic acid molecule of claim 40.

42. An isolated polypeptide comprising the sequence of SEQ ID NO:2, as depicted in **FIG. 1**.

* * * * *